
Maria Condello

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3737576/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A natural product, voacamine, sensitizes paclitaxel-resistant human ovarian cancer cells. Toxicology and Applied Pharmacology, 2022, 434, 115816.	1.3	10
2	Electrochemotherapy with Mitomycin C Potentiates Apoptosis Death by Inhibiting Autophagy in Squamous Carcinoma Cells. Cancers, 2021, 13, 3867.	1.7	4
3	Label-free cell based impedance measurements of ZnO nanoparticles—human lung cell interaction: a comparison with MTT, NR, Trypan blue and cloning efficiency assays. Journal of Nanobiotechnology, 2021, 19, 306.	4.2	7
4	Role of Natural Antioxidant Products in Colorectal Cancer Disease: A Focus on a Natural Compound Derived from Prunus spinosa, Trigno Ecotype. Cells, 2021, 10, 3326.	1.8	14
5	The Exploitation of Liposomes in the Inhibition of Autophagy to Defeat Drug Resistance. Frontiers in Pharmacology, 2020, 11, 787.	1.6	16
6	Voacamine: Alkaloid with its essential dimeric units to reverse tumor multidrug resistance. Toxicology in Vitro, 2020, 65, 104819.	1.1	10
7	Anticancer activity of "Trigno Mâ€; extract of Prunus spinosa drupes, against in vitro 3D and in vivo colon cancer models. Biomedicine and Pharmacotherapy, 2019, 118, 109281.	2.5	23
8	Influence of lipid composition on the ability of liposome loaded voacamine to improve the reversion of doxorubicin resistant osteosarcoma cells. Chemistry and Physics of Lipids, 2019, 223, 104781.	1.5	11
9	Targeting Autophagy to Overcome Human Diseases. International Journal of Molecular Sciences, 2019, 20, 725.	1.8	83
10	Cytotoxic and Apoptotic Activities of Prunus spinosa Trigno Ecotype Extract on Human Cancer Cells. Molecules, 2017, 22, 1578.	1.7	22
11	Exosomes from human colorectal cancer induce a tumor-like behavior in colonic mesenchymal stromal cells. Oncotarget, 2016, 7, 50086-50098.	0.8	124
12	ZnO nanoparticle tracking from uptake to genotoxic damage in human colon carcinoma cells. Toxicology in Vitro, 2016, 35, 169-179.	1.1	66
13	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	4.3	4,701
14	Inclusion of new 5-fluorouracil amphiphilic derivatives in liposome formulation for cancer treatment. MedChemComm, 2015, 6, 1639-1642.	3.5	18
15	High-performance thin-layer chromatography for the evaluation of voacamine intracellular concentration related to its cytotoxic effect. Journal of Pharmaceutical and Biomedical Analysis, 2015, 115, 467-474.	1.4	1
16	Migratory behaviour of tumour cells: a scanning electron microscopy study. Annali Dell'Istituto Superiore Di Sanita, 2015, 51, 139-47.	0.2	7
17	Voacamine Modulates the Sensitivity to Doxorubicin of Resistant Osteosarcoma and Melanoma Cells and Does Not Induce Toxicity in Normal Fibroblasts. Journal of Natural Products, 2014, 77, 855-862.	1.5	21
18	The combined treatment with chloroquine and the enzymatic oxidation products of spermine overcomes multidrug resistance of melanoma M14 ADR2 cells: A new therapeutic approach. International Journal of Oncology, 2014, 45, 1109-1122.	1.4	17

Maria Condello

#	Article	IF	CITATIONS
19	Structural and functional alterations of cellular components as revealed by electron microscopy. Microscopy Research and Technique, 2013, 76, 1057-1069.	1.2	17
20	The thiazole derivative CPTH6 impairs autophagy. Cell Death and Disease, 2013, 4, e524-e524.	2.7	28
21	Electroporation adopting trains of biphasic pulses enhances in vitro and in vivo the cytotoxic effect of doxorubicin on multidrug resistant colon adenocarcinoma cells (LoVo). European Journal of Cancer, 2012, 48, 2236-2243.	1.3	24
22	Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-544.	4.3	3,122
23	The PPAR-Î ³ agonist troglitazone antagonizes survival pathways induced by STAT-3 in recombinant interferon-Î ² treated pancreatic cancer cells. Biotechnology Advances, 2012, 30, 169-184.	6.0	76
24	Platinum(II) chloride indenyl complexes: electrochemical and biological evaluation. Journal of Biological Inorganic Chemistry, 2011, 16, 695-713.	1.1	14
25	Autophagy: Molecular Mechanisms and their Implications for Anticancer Therapies. Current Cancer Drug Targets, 2011, 11, 357-379.	0.8	28
26	Exposure to ZnO nanoparticles induces oxidative stress and cytotoxicity in human colon carcinoma cells. Toxicology and Applied Pharmacology, 2010, 246, 116-127.	1.3	254
27	Synthesis and biological activity of 1,4-dihydrobenzothiopyrano[4,3-c]pyrazole derivatives, novel pro-apoptotic mitochondrial targeted agents. Bioorganic and Medicinal Chemistry, 2009, 17, 326-336.	1.4	26
28	Cytotoxicity of spermine oxidation products to multidrug resistant melanoma M14 ADR2 cells: Sensitization by the MDL 72527 lysosomotropic compound. International Journal of Oncology, 2009, 35, 485-98.	1.4	27
29	The plant alkaloid voacamine induces apoptosis-independent autophagic cell death on both sensitive and multidrug resistant human osteosarcoma cells. Autophagy, 2008, 4, 1020-1033.	4.3	64
30	MDL 72527 and spermine oxidation products induce a lysosomotropic effect and mitochondrial alterations in tumour cells. Biochemical Society Transactions, 2007, 35, 343-348.	1.6	7
31	Autophagy-mediated chemosensitizing effect of the plant alkaloid voacamine on multidrug resistant cells. Toxicology in Vitro, 2007, 21, 197-203.	1.1	36
32	Sensitization of human colon adenocarcinoma cells (LoVo) to reactive oxygen species by a lysosomotropic compound. International Journal of Oncology, 2006, 29, 947.	1.4	3
33	The nitroxide Tempol modulates anthracycline resistance in breast cancer cells. Free Radical Biology and Medicine, 2006, 40, 1409-1418.	1.3	25
34	Toxicity of enzymatic oxidation products of spermine to human melanoma cells (M14): Sensitization by heat and MDL 72527. Biochimica Et Biophysica Acta - Molecular Cell Research, 2006, 1763, 1040-1050.	1.9	35
35	Voacamine, an alkaloid extracted from Peschiera fuchsiaefolia, inhibits P-glycoprotein action in multidrug-resistant tumor cells. International Journal of Oncology, 2005, 27, 1597-603.	1.4	6